Purple Biotech Gets European Patent Intention for NT219 Combinations
Ticker: PPBT · Form: 6-K · Filed: Sep 10, 2025 · CIK: 1614744
Sentiment: bullish
Topics: patent, intellectual-property, drug-development
TL;DR
Purple Biotech snagged a European patent intention for NT219 combos with immuno/MEK drugs - big IP win!
AI Summary
On September 10, 2025, Purple Biotech Ltd. announced it received an intention to grant a European patent for its NT219 drug when used in combination with immunotherapies or MEK inhibitors. This patent, if granted, would cover a significant therapeutic application for the company's lead drug candidate.
Why It Matters
This potential patent grant strengthens Purple Biotech's intellectual property position for NT219, a key asset in its pipeline, potentially enhancing its commercial value and competitive advantage.
Risk Assessment
Risk Level: medium — While a patent intention is positive, the actual grant and its scope, along with the clinical and commercial success of NT219, present ongoing risks.
Key Players & Entities
- Purple Biotech Ltd. (company) — Filer and subject of the announcement
- NT219 (drug) — Drug candidate covered by the patent intention
- September 10, 2025 (date) — Date of the press release and announcement
FAQ
What is the specific indication or disease area the European patent intention for NT219 combinations is intended to cover?
The filing states the patent intention covers NT219 combinations with immunotherapies or MEK inhibitors, but does not specify a particular indication or disease area.
What is the expected timeline for the final grant of the European patent?
The filing does not provide an expected timeline for the final grant of the European patent.
Has Purple Biotech Ltd. previously received patent protection for NT219 in other regions?
This filing does not contain information about previous patent protection for NT219 in other regions.
What is the significance of NT219 to Purple Biotech Ltd.'s overall drug development pipeline?
The filing identifies NT219 as a lead drug candidate, implying its significance to the company's pipeline, especially with the potential for combination therapies.
What are immunotherapies and MEK inhibitors in the context of cancer treatment?
Immunotherapies harness the body's immune system to fight cancer, while MEK inhibitors target specific proteins involved in cell growth and division, often used in certain types of cancer.
Filing Stats: 212 words · 1 min read · ~1 pages · Grade level 13 · Accepted 2025-09-10 08:03:09
Filing Documents
- ea0256749-6k_purple.htm (6-K) — 9KB
- ea025674902ex99-1_purple.htm (EX-99.1) — 14KB
- 0001213900-25-086377.txt ( ) — 24KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. September 10, 2025 PURPLE BIOTECH LTD. By: /s/ Gil Efron Gil Efron Chief Executive Officer 2